MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Ticker SymbolMDXH
Company nameMDxHealth SA
IPO dateJun 26, 2006
CEOMr. Michael K. McGarrity
Number of employees312
Security typeOrdinary Share
Fiscal year-endJun 26
AddressCAP Business Center
CityHERSTAL
Stock exchangeNASDAQ Capital Market Consolidated
CountryBelgium
Postal code4040
Phone3243642070
Websitehttps://mdxhealth.com/
Ticker SymbolMDXH
IPO dateJun 26, 2006
CEOMr. Michael K. McGarrity
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data